Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
642 studies found for:    lupus
Show Display Options
Rank Status Study
21 Recruiting Prospective Evaluation of Decision and Compliance With Antimalarials in Patients With Systemic Lupus
Condition: Systemic Lupus Erythematosus
Intervention: Other: therapeutic education
22 Terminated A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Patients With Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Intervention: Drug: Lupuzor
23 Terminated The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Drug: mycophenolate sodium;   Drug: cyclophosphamide
24 Not yet recruiting Effect of Qi Gong Training on Quality of Life in Patients With Systemic Lupus Erythematous (LuQi)
Condition: Lupus Erythematosus, Systemic
Intervention: Other: Qi Gong
25 Terminated
Has Results
Etanercept for the Treatment of Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Drug: Etanercept;   Drug: Lupus Treatment- Standard of Care;   Drug: Placebo
26 Recruiting Low-dose UVA1 Radiation in Cutaneous Lupus Patients
Condition: Cutaneous Lupus Erythematosus
Intervention: Device: UVA1 radiation treatment
27 Recruiting A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
Condition: Systemic Lupus Erythematosus
Interventions: Drug: CC-220;   Drug: Placebo
28 Terminated Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy
Condition: Lupus Nephritis
Intervention: Biological: Rituximab
29 Not yet recruiting Dissemination of the Lupus Interactive Navigator
Condition: Systemic Lupus Erythematosus
Interventions: Other: LIN_NOW;   Other: LIN_WAIT
30 Completed Phase 3 Study of Tacrolimus (FK506) for Lupus Nephritis: A Placebo Controlled, Double-Blind Multicenter, Comparative Study
Condition: Lupus Nephritis
Intervention: Drug: tacrolimus
31 Unknown  Phase 2 Study of Human Umbilical Cord Derived Mesenchymal Stem Cell for the Treatment of Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Biological: Human Umbilical Cord derived MSCs;   Drug: Cyclophosphamide
32 Completed Study of Methotrexate in Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Intervention: Drug: Methotrexate and folic acid
33 Completed Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Intervention: Drug: SBI-087
34 Completed Functional MRI in Lupus Nephritis
Conditions: Healthy;   Lupus Nephritis
Intervention:
35 Completed
Has Results
A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Anifrolumab 300 mg;   Biological: Anifrolumab 1000 mg;   Other: Placebo
36 Not yet recruiting Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus.
Condition: Lupus Erythematosus
Intervention:
37 Completed Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser
Condition: Cutaneous Lupus Erythematosus
Intervention: Procedure: laser treatment (Candela Vbeam Perfecta™)
38 Completed Safety Study of AMG 557 in Subjects With Lupus Arthritis
Condition: Lupus Arthritis, Systemic Lupus Erythematosus
Interventions: Drug: AMG 557;   Drug: Matching Placebo
39 Unknown  Umbilical Cord Derived Mesenchymal Stem Cells Transplantation for Active and Refractory Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Intervention: Biological: human umbilical cord derived MSC transplantation for SLE
40 Recruiting Duke Lupus Registry
Conditions: Systemic Lupus Erythematosus;   Cutaneous Lupus
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.